Sr. Officer - Finance & Accounts

About Intas

Recruitment Fraud Disclaimer:

Intas Pharmaceuticals does not request or accept any fees during recruitment. If someone asks for payment on our behalf, it is a scam. Please report the incident to the local police or cybercrime unit. Your trust and safety are important to us.

Intas is a leading global pharmaceutical company specializing in the development, manufacturing, and marketing of pharmaceutical formulations. The mission of the company is to address unmet medical and societal needs through a fully integrated pharmaceutical value chain spanning across the world.

Through its subsidiaries, the International presence of Intas includes the following countries: over 85 worldwide, with some of the more important global markets like North America, Europe, Latin America, and the Asia-Pacific under the well-known brand name Accord Healthcare. The rapid expansion has been due to organic growth and strategic acquisitions alone, vindicating its position in some of the important major pharmaceutical markets across the world.

Intas follows high standards of quality, as reflected by products approved for leading global regulatory agencies including USFDA, MHRA, and EMA. Substantial in-house R&D capability, along with the beginning of a focus on highly advanced areas like Biosimilars and New Chemical Entities-Intas continues to push the frontiers of excellence in healthcare.

At Intas, our success is fundamentally built on the strength of our people. Our ongoing commitment is to attract and retain the best talent in the industry while fostering an empowering environment that encourages innovation and excellence. This approach ensures that every employee plays a meaningful role in driving both the companys growth and advancements in global healthcare.

Job Title: Sr. Officer - Finance & Accounts

Job Requisitions No.: 18945

Purpose of Job

Accounts Receivable & CSA Operations Professional with experience in managing receivables, reconciliations, commission validation, financial reporting, audit support, and process improvements for 60+ CSA accounts. Skilled in SAP and Pharmanet reconciliation, outstanding management, stakeholder coordination, financial controls, and driving operational efficiency through process standardisation and system enhancements.

Roles and Responsibilites

• Reviewing proper transfer of the receipt transactions from Pharmanet to SAP on regular basis for 60 CSA.
• Preparation & circulation of the overdue outstanding report for 60 CSA, so the account can be settled regularly with them, and further decisions can be made.
• Clearing/Knock-off of the unsettled balances open in customer accounts on regular basis to avoid building of unnecessary open items.
• Review of the outstanding position for 60 CSA on fortnightly basis and sharing a review comparison where it is as per the agreed terms with CSA.
• Preparation & circulation of monthly CN/DN listing with reason and purpose for issuing of same for 60 CSA.
• Monthly Cheque Bounce summary preparation & circulation for all the CSA along-with reasons for bounce.
• Monthly Recon of customer balances as per Pharmanet V/s SAP for all the CSA and resolving of the differences co-ordinating with IT.
• Review of the monthly commission calculations for all the CSA to ensure pay-out of correct commissions to CSA.
• Preparing & circulating the monthly interest liability on the deposits made by all CSA for booking of monthly expense provision against same

• M.Com is required.
• Freshers can also apply.

  Location:

• Head Office, Ahmedabad, GJ, IN, 380054
• Travel: 0% - 25%
• Life at Intas Pharmaceuticals

For over three decades, Intas has thrived due to the exceptional talent of its people. Our growth is fueled by a dynamic environment that nurtures individual potential while fostering collaboration and collective success. We believe that when diverse skills and perspectives unite under a shared purpose and value system, we can achieve remarkable outcomes, driving innovation and excellence across the pharmaceutical landscape.

Date: 13 Oct 2026